Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
5/22/25 21:47 | 5/20/25 | REPL | Health | BioPrd | Biological Products, (No Diag | Astley-Sparke Philip | MA | D | 1 | S | -260 | 8.06 | 0 | -32 | 1,405 | D | ||||||||||||||||
5/22/25 21:46 | 5/20/25 | REPL | Health | BioPrd | Biological Products, (No Diag | Xynos Konstantinos | MA | O | Chief Me | 1 | S | -64 | 8.06 | 0 | -8 | 147 | D | |||||||||||||||
5/22/25 21:45 | 5/20/25 | REPL | Health | BioPrd | Biological Products, (No Diag | Schwendenman Andrew | MA | O | Chief Ac | 1 | S | -26 | 8.05 | 0 | -3 | 68 | D | |||||||||||||||
5/22/25 21:44 | 5/20/25 | REPL | Health | BioPrd | Biological Products, (No Diag | Patel Sushil | MA | DO | CEO | 1 | S | -202 | 8.06 | 0 | -25 | 344 | D | |||||||||||||||
5/22/25 21:44 | 5/20/25 | REPL | Health | BioPrd | Biological Products, (No Diag | Hill Emily Luisa | MA | O | CFO | 1 | S | -20 | 8.05 | 0 | -3 | 144 | D | |||||||||||||||
5/22/25 21:42 | 5/20/25 | REPL | Health | BioPrd | Biological Products, (No Diag | Sarchi Christopher | MA | O | Chief Co | 1 | S | -30 | 8.05 | 0 | -4 | 128 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |